Greenphire introduces new budget tool to streamline clinical trails
Category: #health  By Pankaj Singh  Date: 2020-06-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

Greenphire introduces new budget tool to streamline clinical trails

Greenphire Inc, one of the world’s leading companies in financial lifecycle management for clinical trials, has reportedly launched a new budget development solution named EnvisiX to address the budgeting challenges experienced by CROs and global sponsors during study start-up. The company has developed a new tool to streamline clinical trials for CROs and sponsors and reduces guesswork during the budgeting phase to offer a smarter, more efficient workflow.

According to sources, EnvisiX effortlessly integrates with the company’s industry-leading site payment solution eClinicalGPS. From budget creation, negotiation, execution, management, to tracking of global investigator grants, the integration would help companies to facilitate efficiency and simplicity throughout a clinical trial.

Moreover, the tool gives access to the contemporary and robust investigator grant payment data in the industry. It also helps sponsors and CROs to streamline the negotiation workflow for enhanced transparency, collaboration, transparency, and management of adjustments, rates, adjudications, approvals, and more.

Speaking on which, Jim Murphy, CEO of Greenphire said that the company is committed to engineering workflow and data solutions that renovate business processes, decreasing the administrative burden and enhancing process effectiveness at every step of the clinical study.

Mr. Murphy added that EnvisiX will help stakeholders to gain visibility and control over the fragmented and manual budget build and negation workflows, ensuring enhanced accuracy and speed along the way.

For years, CROs and sponsors were not satisfied with their study start-up process and then the company built EnvisiX to solve issues related to existing workflows and solutions available in the market today, said, Kyle Cunningham, Chief Product Officer (CPO) at Greenphire.

Mr. Cunningham added that EnvisiX provides clients with user-friendly and streamlined experience for building a budget and eventually to enable defensibility, maximized confidence, and end-to-end efficiency through direct integration and a feedback loop with the company’s leading site payment solution eClinicalGPS.

Source Credit - https://www.wfmz.com/news/pr_newswire/pr_newswire_pennsylvania/greenphire-launches-new-clinical-trial-budget-build-and-negotiation-solution-envisix/article_b7d93a66-8775-529e-82e9-94d065ae4433.html



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...